Finance

Lists
Why is ZVSA up 3,46%?
Dive Deeper
ZVSA:OTCMKTS
Zyversa Therapeutics Inc
USD 0,082
+3,46%
(+0,0028) 1D
6 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZVSA...
Open
USD 0,10
High
USD 0,10
Low
USD 0,08
Mkt. cap
665,89 k
Avg. vol.
6,25 k
Volume
2,40 k
52-wk high
USD 0,30
52-wk low
USD 0,08
EPS
-USD 3,32
Beta
0,85
Shares outstanding
8,10 m
No. of employees
6
Open
USD 0,10
High
USD 0,10
Low
USD 0,08
Mkt. cap
665,89 k
Avg. vol.
6,25 k
Volume
2,40 k
52-wk high
USD 0,30
52-wk low
USD 0,08
EPS
-USD 3,32
Beta
0,85
Shares outstanding
8,10 m
No. of employees
6
News stories
From web sources and news partners
About Zyversa Therapeutics Inc
CEO-
Employees6
Founded2014
HeadquartersWeston, Florida, Verenigde State van Amerika
Sector-
Websitezyversa.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Jun. 2025
Sep. 2025
Des. 2025
Mrt. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
409,94 k
365,05 k
79,24 k
57,62 k
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,63 m
1,74 m
472,62 k
1,25 m
Operating expense
2,04 m
2,10 m
551,86 k
1,30 m
Total operating expenses
2,04 m
2,10 m
551,86 k
1,30 m
Operating income
-2,04 m
-2,10 m
-551,86 k
-1,30 m
Other non operating income
-37,15 k
226,26 k
-196,31 k
-12,17 k
EBT including unusual items
-2,21 m
-20,66 m
-678,57 k
-1,79 m
EBT excluding unusual items
-2,21 m
-2,01 m
-880,43 k
-1,45 m
Income tax expense
-
-851,66 k
-
-
Effective tax rate
-
4,12%
-
-
Other operating expenses
-
-
-
-
Net income
-2,21 m
-19,81 m
-678,57 k
-1,79 m
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-130,04 k
-131,35 k
-132,26 k
-132,51 k
Net interest expenses
-130,04 k
-131,35 k
-132,26 k
-132,51 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-2,04 m
-2,10 m
-550,12 k
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme